-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Neutral on Biogen, Raises Price Target to $225

Benzinga·10/29/2026 14:44:05
Listen to the news
Wedbush analyst Laura Chico maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $212 to $225.